Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.


Journal

Genetics
ISSN: 1943-2631
Titre abrégé: Genetics
Pays: United States
ID NLM: 0374636

Informations de publication

Date de publication:
04 2020
Historique:
received: 07 11 2019
accepted: 06 02 2020
pubmed: 26 2 2020
medline: 22 4 2021
entrez: 26 2 2020
Statut: ppublish

Résumé

Systematic genetic interaction profiles can reveal the mechanisms-of-action of bioactive compounds. The imipridone ONC201, which is currently in cancer clinical trials, has been ascribed a variety of different targets. To investigate the genetic dependencies of imipridone action, we screened a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) knockout library in the presence of either ONC201 or its more potent analog ONC212. Loss of the mitochondrial matrix protease CLPP or the mitochondrial intermediate peptidase MIPEP conferred strong resistance to both compounds. Biochemical and surrogate genetic assays showed that impridones directly activate CLPP and that MIPEP is necessary for proteolytic maturation of CLPP into a catalytically competent form. Quantitative proteomic analysis of cells treated with ONC212 revealed degradation of many mitochondrial as well as nonmitochondrial proteins. Prompted by the conservation of ClpP from bacteria to humans, we found that the imipridones also activate ClpP from

Identifiants

pubmed: 32094149
pii: genetics.119.302851
doi: 10.1534/genetics.119.302851
pmc: PMC7153937
doi:

Substances chimiques

ADEP4 acyldepsipeptide 0
Anti-Bacterial Agents 0
Antineoplastic Agents 0
Depsipeptides 0
Escherichia coli Proteins 0
Imidazoles 0
Pyridines 0
Pyrimidines 0
TIC10 compound 9U35A31JAI
ClpP protease, E coli EC 3.4.21.92
ClpP protein, human EC 3.4.21.92
Endopeptidase Clp EC 3.4.21.92
Metalloendopeptidases EC 3.4.24.-
mitochondrial intermediate peptidase EC 3.4.24.59
Rifampin VJT6J7R4TR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1103-1120

Subventions

Organisme : CIHR
ID : FDN-167277
Pays : Canada
Organisme : CIHR
ID : FDN-148463
Pays : Canada

Informations de copyright

Copyright © 2020 Jacques et al.

Références

Mol Cell. 2016 Mar 3;61(5):667-676
pubmed: 26942671
Chem Biol. 2011 Sep 23;18(9):1167-78
pubmed: 21944755
Mol Cell Biol. 2017 Dec 13;38(1):
pubmed: 29038160
Cell Chem Biol. 2018 Aug 16;25(8):1017-1030.e9
pubmed: 30126533
Neoplasia. 2018 Jan;20(1):80-91
pubmed: 29216597
BMC Genomics. 2009 Jul 01;10:291
pubmed: 19570206
J Infect Dis. 2008 Apr 15;197(8):1079-81
pubmed: 18419525
Nat Rev Mol Cell Biol. 2015 Jun;16(6):345-59
pubmed: 25970558
ACS Chem Biol. 2019 Nov 15;14(11):2349-2360
pubmed: 31241890
Clin Cancer Res. 2019 Apr 1;25(7):2305-2313
pubmed: 30559168
ACS Chem Biol. 2018 Jun 15;13(6):1413-1425
pubmed: 29775273
Oncotarget. 2016 Nov 8;7(45):74380-74392
pubmed: 27602582
ACS Med Chem Lett. 2017 Oct 19;8(11):1171-1176
pubmed: 29152050
Cell Cycle. 2017 Oct 2;16(19):1790-1799
pubmed: 28489985
Int J Mol Sci. 2019 May 07;20(9):
pubmed: 31067645
Sci Signal. 2016 Feb 16;9(415):ra18
pubmed: 26884600
Chembiochem. 2014 Oct 13;15(15):2216-20
pubmed: 25212124
Annu Rev Biochem. 2011;80:587-612
pubmed: 21469952
Mol Microbiol. 1998 Mar;27(5):899-914
pubmed: 9535081
ACS Infect Dis. 2019 Nov 8;5(11):1915-1925
pubmed: 31588734
BMC Microbiol. 2012 Nov 13;12:259
pubmed: 23148795
Nat Rev Microbiol. 2019 Mar;17(3):141-155
pubmed: 30683887
Dev Cell. 2007 Oct;13(4):467-80
pubmed: 17925224
Cancer Cell. 2015 Jun 8;27(6):864-76
pubmed: 26058080
J Antibiot (Tokyo). 2019 Mar;72(3):185-188
pubmed: 30479393
Cancer Cell. 2019 Jul 8;36(1):84-99.e8
pubmed: 31287994
Angew Chem Int Ed Engl. 2018 Oct 26;57(44):14602-14607
pubmed: 30129683
Nat Commun. 2019 Nov 19;10(1):5221
pubmed: 31745082
Curr Opin Chem Biol. 2011 Feb;15(1):66-78
pubmed: 21093351
Sci Transl Med. 2019 Sep 11;11(509):
pubmed: 31511426
Front Mol Biosci. 2017 May 22;4:34
pubmed: 28589125
J Nat Prod. 2016 Apr 22;79(4):1193-7
pubmed: 26967980
Sci Signal. 2016 Feb 16;9(415):ra17
pubmed: 26884599
Lancet Infect Dis. 2018 Jul;18(7):e183-e198
pubmed: 29580819
J Med Chem. 2016 Jan 28;59(2):624-46
pubmed: 26818454
Nat Med. 2005 Oct;11(10):1082-7
pubmed: 16200071
Genome Announc. 2015 Sep 24;3(5):
pubmed: 26404610
J Am Chem Soc. 2014 Feb 5;136(5):1922-9
pubmed: 24422534
Cell Rep. 2017 Nov 14;21(7):1746-1756
pubmed: 29141210
Cancer Cell. 2019 May 13;35(5):721-737.e9
pubmed: 31056398
Antimicrob Agents Chemother. 2010 Feb;54(2):602-9
pubmed: 19995928
Oncotarget. 2018 Apr 6;9(26):18454-18479
pubmed: 29719618
Leukemia. 2019 Dec;33(12):2805-2816
pubmed: 31127149
J Biol Chem. 1990 Jul 25;265(21):12546-52
pubmed: 2197276
PLoS One. 2014 Jul 29;9(7):e103141
pubmed: 25072814
J Struct Biol. 2004 Dec;148(3):338-52
pubmed: 15522782
J Antibiot (Tokyo). 2017 Apr;70(4):366-377
pubmed: 27899793
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E8045-E8052
pubmed: 28874591
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Annu Rev Physiol. 2018 Feb 10;80:413-429
pubmed: 29433415
ACS Chem Biol. 2019 May 17;14(5):1020-1029
pubmed: 31021596
Nature. 2016 Jan 21;529(7586):336-43
pubmed: 26791724
Mol Cell. 2003 Mar;11(3):671-83
pubmed: 12667450
PLoS Biol. 2016 Jul 07;14(7):e1002507
pubmed: 27389535
Mol Cell Proteomics. 2018 Oct;17(10):2051-2067
pubmed: 30007914
FEBS Lett. 1995 Dec 18;377(2):249-52
pubmed: 8543061
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Mol Cell Proteomics. 2012 Mar;11(3):M111.014050
pubmed: 22278370
Exp Cell Res. 2012 Nov 1;318(18):2335-43
pubmed: 22841477
Biochim Biophys Acta. 2002 Sep 2;1592(1):63-77
pubmed: 12191769
Chem Biol. 2010 Sep 24;17(9):959-69
pubmed: 20851345
J Biol Chem. 2017 Jun 16;292(24):10035-10047
pubmed: 28476889
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Biochemistry (Mosc). 2005 Feb;70(2):267-74
pubmed: 15807669
EMBO J. 2002 Sep 2;21(17):4411-9
pubmed: 12198143
Nature. 2014 Jun 26;510(7506):503-6
pubmed: 24965651
Sci Transl Med. 2013 Feb 6;5(171):171ra17
pubmed: 23390247
ChemMedChem. 2006 Jul;1(7):689-93
pubmed: 16902918
Braz J Microbiol. 2017 Oct - Dec;48(4):617-628
pubmed: 28754299
Nature. 2013 Nov 21;503(7476):365-70
pubmed: 24226776
Mol Microbiol. 2016 Jul;101(2):194-209
pubmed: 26919556

Auteurs

Samuel Jacques (S)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada.

Almer M van der Sloot (AM)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada am.van.der.sloot@umontreal.ca md.tyers@umontreal.ca.

Caroline C Huard (C)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada.

Jasmin Coulombe-Huntington (J)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada.

Sarah Tsao (S)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada.

Sylvain Tollis (S)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada.

Thierry Bertomeu (T)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada.

Elizabeth J Culp (EJ)

David Braley Center for Antibiotic Discovery, McMaster University, Hamilton, Ontario L8S 4L8, Canada.
Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4K1, Canada.

Daniel Pallant (D)

David Braley Center for Antibiotic Discovery, McMaster University, Hamilton, Ontario L8S 4L8, Canada.
Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4K1, Canada.

Michael A Cook (MA)

David Braley Center for Antibiotic Discovery, McMaster University, Hamilton, Ontario L8S 4L8, Canada.
Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4K1, Canada.

Eric Bonneil (E)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada.

Pierre Thibault (P)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada am.van.der.sloot@umontreal.ca md.tyers@umontreal.ca.

Gerard D Wright (GD)

David Braley Center for Antibiotic Discovery, McMaster University, Hamilton, Ontario L8S 4L8, Canada.
Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4K1, Canada.

Mike Tyers (M)

Institute for Research in Immunology and Cancer, University of Montréal, Quebec H3T 1JH, Canada am.van.der.sloot@umontreal.ca md.tyers@umontreal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH